Margaret Beaudoin - 16 Jun 2021 Form 3 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Vice President, Finance
Signature
/s/ Andrew Ashe, Attorney-in-Fact
Issuer symbol
VERV
Transactions as of
16 Jun 2021
Net transactions value
$0
Form type
3
Filing time
16 Jun 2021, 19:29:01 UTC
Next filing
21 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VERV Stock Option (right to buy) 16 Jun 2021 Common Stock 10,799 $8.24 Direct F1
holding VERV Stock Option (right to buy) 16 Jun 2021 Common Stock 53,998 $2.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 12, 2021 for 10,799 shares. 25% the shares underlying the option will vest on February 1, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until February 1, 2025.
F2 The option was granted on September 16, 2020 for 53,998 shares. 25% the shares underlying the option will vest on June 8, 2021, and the remainder are scheduled to vest in equal monthly installments thereafter until June 8, 2024.

Remarks:

Exhibit Index: 24.1 Power of Attorney